Clarithromycin
Biaxin, Prevpac, Voquezna Triple (clarithromycin) is a small molecule pharmaceutical. Clarithromycin was first approved as Biaxin on 1991-10-31. It is used to treat bacterial infections, bronchitis, chlamydia infections, duodenal ulcer, and haemophilus infections amongst others in the USA. The pharmaceutical is active against androgen receptor.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Combinations
Voquezna triple (generic drugs available since 2004-06-24, discontinued: Prevpac)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Amoxicillin
+
Clarithromycin
+
Lansoprazole
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
PREVPAC (COPACKAGED) | Takeda | N-050757 DISCN | 1997-12-02 | 1 products, RLD |
Hide discontinued
Amoxicillin
+
Clarithromycin
+
Omeprazole
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN | Cumberland Pharmaceuticals | N-050824 DISCN | 2011-02-08 | 1 products, RLD |
Hide discontinued
Amoxicillin
+
Clarithromycin
+
Vonoprazan fumarate
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
VOQUEZNA TRIPLE PAK | Phathom Pharmaceuticals | N-215152 PEND | 2022-05-03 | 1 products, RLD |
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
biaxin | New Drug Application | 2012-02-22 |
clarithromycin | ANDA | 2023-06-16 |
prevpac | New Drug Application | 2010-03-15 |
voquezna dual pak voquezna triple pak | New Drug Application | 2022-06-21 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
bacterial infections | — | D001424 | A49 |
bronchitis | — | D001991 | J40 |
chlamydia infections | EFO_0007205 | D002690 | A74.9 |
duodenal ulcer | EFO_0004607 | D004381 | K26 |
haemophilus infections | EFO_1001127 | D006192 | — |
helicobacter infections | EFO_1000961 | D016481 | — |
infectious skin diseases | — | D012874 | — |
mycoplasma pneumonia | EFO_0007387 | D011019 | J15.7 |
nontuberculous mycobacterium infections | EFO_0007461 | D009165 | A31.9 |
otitis media | EFO_0004992 | D010033 | H66.9 |
Show 5 more
Agency Specific
FDA
EMA
Expiration | Code | ||
---|---|---|---|
AMOXICILLIN / CLARITHROMYCIN / VONOPRAZAN FUMARATE, VOQUEZNA TRIPLE PAK, PHATHOM | |||
2032-05-03 | GAIN | ||
2027-05-03 | NCE |
ATC Codes
A: Alimentary tract and metabolism drugs
— A02: Drugs for acid related disorders
— A02B: Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord)
— A02BD: Combinations for eradication of helicobacter pylori
— A02BD04: Pantoprazole, amoxicillin and clarithromycin
— A02BD05: Omeprazole, amoxicillin and clarithromycin
— A02BD06: Esomeprazole, amoxicillin and clarithromycin
— A02BD07: Lansoprazole, amoxicillin and clarithromycin
— A02BD09: Lansoprazole, clarithromycin and tinidazole
— A02BD11: Pantoprazole, amoxicillin, clarithromycin and metronidazole
— A02BD12: Rabeprazole, amoxicillin and clarithromycin
— A02BD14: Vonoprazan, amoxicillin and clarithromycin
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01F: Macrolides, lincosamides and streptogramins
— J01FA: Macrolides
— J01FA09: Clarithromycin
HCPCS
No data
Clinical
Clinical Trials
48 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neuromuscular blockade | D019148 | — | 1 | — | 4 | 4 | 9 | ||
Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | — | 1 | 3 | — | 4 |
General anesthesia | D000768 | — | — | — | 1 | 3 | 4 | ||
Anesthesia | D000758 | — | — | — | 1 | 2 | 3 | ||
Delayed emergence from anesthesia | D055191 | — | — | — | 2 | 1 | 3 | ||
Postoperative complications | D011183 | — | — | — | 1 | 1 | 2 | ||
Critical illness | D016638 | — | — | 1 | 1 | — | 2 | ||
Emergence delirium | D000071257 | — | — | — | 1 | 1 | 2 | ||
Patient-controlled analgesia | D016058 | — | — | — | 1 | — | 1 | ||
Arthroplasty | D001178 | — | — | — | 1 | — | 1 |
Show 9 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Renal insufficiency | D051437 | HP_0000083 | N19 | — | 1 | — | — | — | 1 |
Intraocular pressure | D007429 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Postoperative pain | D010149 | G89.18 | — | — | — | — | 1 | 1 | |
Urologic diseases | D014570 | N39.9 | — | — | — | — | 1 | 1 | |
Gender identity | D005783 | — | — | — | — | 1 | 1 | ||
Post-cardiac arrest syndrome | D000080942 | — | — | — | — | 1 | 1 | ||
Brain neoplasms | D001932 | EFO_0003833 | C71 | — | — | — | — | 1 | 1 |
Intracranial aneurysm | D002532 | EFO_0003870 | I67.1 | — | — | — | — | 1 | 1 |
Intratracheal intubation | D007442 | — | — | — | — | 1 | 1 | ||
Intra-abdominal hypertension | D059325 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | CLARITHROMYCIN |
INN | clarithromycin |
Description | Clarithromycin is the 6-O-methyl ether of erythromycin A, clarithromycin is a macrolide antibiotic used in the treatment of respiratory-tract, skin and soft-tissue infections. It is also used to eradicate Helicobacter pylori in the treatment of peptic ulcer disease. It prevents bacteria from growing by interfering with their protein synthesis. It has a role as an antibacterial drug, a protein synthesis inhibitor, an environmental contaminant and a xenobiotic. |
Classification | Small molecule |
Drug class | antibiotics (Streptomyces strain) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O |
Identifiers
PDB | — |
CAS-ID | 81103-11-9 |
RxCUI | 21212 |
ChEMBL ID | CHEMBL1741 |
ChEBI ID | 3732 |
PubChem CID | 84029 |
DrugBank | DB01211 |
UNII ID | H1250JIK0A (ChemIDplus, GSRS) |
Target
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 23,258 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,566 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more